CLTC, which is upregulated in tumor tissues, promotes tumorigenesis by altering the cellular response to TGF-β and is considered a potential biomarker for assessing prognosis and treatment efficacy in HCC (50). This evidence concerns the gene TGFB1 and neoplasm.